ATR inhibitors are a class of targeted cancer therapies that inhibit the activity of the Ataxia Telangiectasia and Rad3-related (ATR) protein kinase. ATR plays a critical role in the DNA damage response (DDR) pathway by activating cell cycle checkpoints and facilitating DNA repair. By inhibiting ATR, these drugs aim to prevent cancer cells from repairing their DNA, leading to cell death.
